期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 15, 期 12, 页码 1391-1419出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.1115720
关键词
Autoimmune encephalitis; antibodies to neuronal cell surface antigens; immune therapy; treatment; limbic encephalitis; NMDAR; LGI1; Caspr2; AMPAR
资金
- National Health and Medical Research Council (Australia)
- Petre Foundation (Australia)
- National Health and Medical Research Council
- MS Research Australia
- Star Scientific Foundation
- Pfizer Neuroscience
- Tourette Syndrome Association
- University of Sydney
- Biogen-Idec
- Bristol-Myers Squibb
We have reviewed the literature of immune therapy in autoimmune encephalitis associated with antibodies to cell surface antigens including N-methyl-D-aspartate receptor (NMDAR), leucine-rich, glioma-inactivated protein-1 (LGI1), contactin-associated protein-2 (Caspr2), the -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), -aminobutyric acid-A receptor (GABAAR), -aminobutyric acid-B receptor (GABABR), Glycine R and other rarer antigens. Most studies are retrospective cohorts, and there are no randomised controlled trials. Most clinicians use first-line therapy (steroids, intravenous immunoglobulin, plasma exchange), and if severe or refractory, second-line therapy (rituximab, cyclophosphamide). When present, tumours should be removed. There are common therapeutic themes emerging. Firstly, patients given immune therapy do better and relapse less than patients given no treatment. Secondly, patients given early treatment do better. And thirdly, when patients fail first-line therapy, second-line therapy improves outcomes and reduces relapses. Given the retrospective uncontrolled data, the literature has inherent bias, including severity and reporting bias.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据